A mouse model involving the human papillomavirus type-16 oncogenes develops cervical cancers by lesional stages analogous to those in humans. In this study the angiogenic phenotype was characterized, revealing intense angiogenesis in high-grade cervical intraepithelial neoplasias (CIN-3) and carcinomas. MMP-9, a proangiogenic protease implicated in mobilization of VEGF, appeared in the stroma concomitant with the angiogenic switch, expressed by infiltrating macrophages, similar to what has been observed in humans. Preclinical trials sought to target MMP-9 and angiogenesis with a prototypical MMP inhibitor and with a bisphosphonate, zoledronic acid (ZA), revealing both to be antiangiogenic, producing effects comparable to a Mmp9 gene KO in impairing angiogenic switching, progression of premalignant lesions, and tumor growth. ZA therapy increased neoplastic epithelial and endothelial cell apoptosis without affecting hyperproliferation, indicating that ZA was not antimitotic. The analyses implicated cellular and molecular targets of ZA’s actions: ZA suppressed MMP-9 expression by infiltrating macrophages and inhibited metalloprotease activity, reducing association of VEGF with its receptor on angiogenic endothelial cells. Given its track record in clinical use with limited toxicity, ZA holds promise as an “unconventional” MMP-9 inhibitor for antiangiogenic therapy of cervical cancer and potentially for additional cancers and other diseases where MMP-9 expression by infiltrating macrophages is evident.
Enrico Giraudo, Masahiro Inoue, Douglas Hanahan
Title and authors | Publication | Year |
---|---|---|
Tumor-associated macrophages as incessant builders and destroyers of the cancer stroma
M Liguori, G Solinas, G Germano, A Mantovani, P Allavena |
Cancers | 2011 |
From Tumor Immunosuppression to Eradication: Targeting Homing and Activity of Immune Effector Cells to Tumors
O Draghiciu, HW Nijman, T Daemen |
Clinical and Developmental Immunology | 2011 |
Fibroblast activation protein-α promotes tumor growth and invasion of breast cancer cells through non-enzymatic functions
Y Huang, AE Simms, A Mazur, S Wang, NR León, B Jones, N Aziz, T Kelly |
Clinical & Experimental Metastasis | 2011 |
Formation of VEGF isoform-specific spatial distributions governing angiogenesis: computational analysis
P Vempati, AS Popel, FM Gabhann |
BMC Systems Biology | 2011 |
Potential pathophysiological mechanisms in osteonecrosis of the jaw
R Landesberg, V Woo, S Cremers, M Cozin, D Marolt, G Vunjak-Novakovic, S Kousteni, S Raghavan |
Annals of the New York Academy of Sciences | 2011 |
Macrophage Binding to Receptor VCAM-1 Transmits Survival Signals in Breast Cancer Cells that Invade the Lungs
Q Chen, XH Zhang, J Massagué |
Cancer Cell | 2011 |
Tumour macrophages as potential targets of bisphosphonates
TL Rogers, I Holen |
Journal of Translational Medicine | 2011 |
Tumor-Recruited Neutrophils and Neutrophil TIMP-Free MMP-9 Regulate Coordinately the Levels of Tumor Angiogenesis and Efficiency of Malignant Cell Intravasation
EM Bekes, B Schweighofer, TA Kupriyanova, E Zajac, VC Ardi, JP Quigley, EI Deryugina |
The American Journal of Pathology | 2011 |
MMP-9 gene deletion mitigates microvascular loss in a model of ischemic acute kidney injury
SY Lee, M Hörbelt, HE Mang, NL Knipe, RL Bacallao, Y Sado, TA Sutton |
AJP Renal Physiology | 2011 |
CC chemokine receptor 5 deletion impairs macrophage activation and induces adverse remodeling following myocardial infarction
R Zamilpa, R Kanakia, JC 4th, Q Dai, GP Escobar, H Martinez, F Jimenez, SS Ahuja, ML Lindsey |
American journal of physiology. Heart and circulatory physiology | 2011 |
Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours
AJ Nicol, H Tokuyama, SR Mattarollo, T Hagi, K Suzuki, K Yokokawa, M Nieda |
British Journal of Cancer | 2011 |
Bisphosphonates Inhibit Expression of p63 by Oral Keratinocytes
EL Scheller, CM Baldwin, S Kuo, NJ D'Silva, SE Feinberg, PH Krebsbach, PC Edwards |
Journal of dental research | 2011 |
Significance of combination therapy of zoledronic acid and gemcitabine on pancreatic cancer
M Zhao, Y Tominaga, K Ohuchida, K Mizumoto, L Cui, S Kozono, H Fujita, R Maeyama, H Toma, M Tanaka |
Cancer Science | 2011 |
Proteolytic networks in cancer
SD Mason, JA Joyce |
Trends in Cell Biology | 2011 |
Metastasis: tumor cells becoming MENAcing
F Gertler, J Condeelis |
Trends in Cell Biology | 2011 |
Enhanced anti-tumor activity and safety profile of targeted nano-scaled HPMA copolymer-alendronate-TNP-470 conjugate in the treatment of bone malignances
E Segal, H Pan, L Benayoun, P Kopečková, Y Shaked, J Kopeček, R Satchi-Fainaro |
Biomaterials | 2011 |
Vγ9Vδ2 T cell-based immunotherapy in hematological malignancies: from bench to bedside
B Castella, C Vitale, M Coscia, M Massaia |
Cellular and Molecular Life Sciences | 2011 |
Novel Therapy to Reverse the Cellular Effects of Bisphosphonates on Primary Human Oral Fibroblasts
M Cozin, BM Pinker, K Solemani, JM Zuniga, SC Dadaian, S Cremers, R Landesberg, S Raghavan |
Journal of Oral and Maxillofacial Surgery | 2011 |
Monitoring mmp-9 gene expression in stromal cells using a novel transgenic mouse model
K Biron-Pain, Y St-Pierre |
Cellular and Molecular Life Sciences | 2011 |
Macrophage-Dependent Cleavage of the Laminin Receptor α6β1 in Prostate Cancer
IC Sroka, CP Sandoval, H Chopra, JM Gard, SC Pawar, AE Cress |
Molecular cancer research : MCR | 2011 |
Myeloid Biomarkers Associated with Glioblastoma Response to Anti-VEGF Therapy with Aflibercept
JF de Groot, Y Piao, H Tran, M Gilbert, HK Wu, J Liu, BN Bekele, T Cloughesy, M Mehta, HI Robins, A Lassman, L DeAngelis, K Camphausen, A Chen, WK Yung, M Prados, PY Wen, JV Heymach |
Clinical cancer research | 2011 |
Direct antitumour activity of zoledronic acid: preclinical and clinical data.
Bosch-Barrera J, Merajver SD, Menéndez JA, Van Poznak C |
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico | 2011 |
Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer.
Goedegebuure P, Mitchem JB, Porembka MR, Tan MC, Belt BA, Wang-Gillam A, Gillanders WE, Hawkins WG, Linehan DC |
Current cancer drug targets | 2011 |